Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week: Big Pharmas Hoard Cash, But Aren’t Buying Yet In 2013

Executive Summary

DOTW digs into a Moody’s report detailing which companies’ balance sheets have the most cash, even if the pharmas that made the cut haven’t been putting their purchasing power to work. In addition, details on Valeant’s latest dermatology acquisition, Merck’s deal with Cerecor for a portfolio of COMT assets, Janssen’s European cancer research tie-up, and an NPS/Takeda deal for orphan drugs.

You may also be interested in...



Deals Of The Week: Pfizer Management Updates Thoughts On Split

Pfizer top management hasn’t yet decided whether it will divide in two or stop at a “virtual split.” Plus updates on Lundbeck/Otsuka, Shire/SARcode, AstraZeneca/Actavis, and more.

Better Late Than Never, J&J’s Innovation Centers Start Opening For Business

J&J’s new London innovation center has just opened and Boston, San Francisco and Shanghai sites are soon to follow. A J&J executive providing an update in NY faced questions from a somewhat skeptical audience of potential customers, revealing nuances and new information about how the centers will operate.

Valeant Continues Buying Spree With $2.6B Acquisition Of Medicis

The specialty pharma adds to its dermatology portfolio with a proposed acquisition of Scottsdale, Ariz.-based Medicis.

Related Content

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

PS055210

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel